Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $4.8 million.

  • Protalix BioTherapeutics' Change in Receivables rose 15788.47% to $4.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.5 million, marking a year-over-year increase of 28333.58%. This contributed to the annual value of -$2.3 million for FY2024, which is 64135.51% down from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Change in Receivables is $4.8 million, which was up 15788.47% from $4.6 million recorded in Q2 2025.
  • Protalix BioTherapeutics' 5-year Change in Receivables high stood at $7.1 million for Q2 2024, and its period low was -$8.4 million during Q3 2024.
  • Over the past 5 years, Protalix BioTherapeutics' median Change in Receivables value was $2.3 million (recorded in 2025), while the average stood at $637105.3.
  • In the last 5 years, Protalix BioTherapeutics' Change in Receivables soared by 25497.91% in 2023 and then crashed by 29449.73% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Change in Receivables stood at -$3.0 million in 2021, then plummeted by 47.81% to -$4.5 million in 2022, then rose by 16.41% to -$3.8 million in 2023, then soared by 120.0% to $752000.0 in 2024, then soared by 544.81% to $4.8 million in 2025.
  • Its Change in Receivables was $4.8 million in Q3 2025, compared to $4.6 million in Q2 2025 and $2.3 million in Q1 2025.